



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)
from Capital District Health Authority/Cancer Care Nova Scotia**

**Guidelines for the Role of Lapatinib / Capecitabine in HER-2 Positive Advanced or
Metastatic Breast Cancer (MBC)**

Approved Use:

Lapatinib / Capecitabine: In **combination** as a **treatment option** in patients with **HER-2 positive** advanced or MBC with trastuzumab refractory disease (previously treated with trastuzumab alone or chemotherapy such as a taxane and/or vinorelbine) who have an ECOG performance status of 0 to 2 and choose to receive systemic chemotherapy. No single agent lapatinib is currently recommended. Patients with previous exposure to capecitabine are not considered eligible.

- This policy recommendation represents a **new guideline document** and a restriction of lapatinib / capecitabine as a treatment option in HER-2 positive patients with advanced/MBC with trastuzumab refractory disease.